PRNewsWire
23 Jun 2026, 10:43 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Culper Research alleges ADMA Biologics engaged in a channel stuffing scheme to report 20% revenue growth in 2025 when real growth was actually -3%. — Allegations of financial fraud and fabricated growth are severe catalysts for long-term valuation collapse and loss of investor trust.
-0.90A securities fraud class action lawsuit has been filed against ADMA Biologics and its senior executives. — Legal action introduces significant litigation risk, potential settlement costs, and regulatory scrutiny.
-0.60Cantor downgraded ADMA Biologics' stock rating following the publication of the short report. — Institutional downgrades typically trigger further sell-offs and reduce the stock's attractiveness to institutional investors.
-0.40Continue reading
6 related stories
Top 1 mover · tap to explore
ADMA's stock price plummeted approximately 29% over a short period in March 2026 following the allegations. — This confirms the market's immediate negative reaction to the fraud claims, though the move has already occurred.
-0.30Which stocks this story touches
The company is facing a securities fraud class action lawsuit and allegations of channel stuffing that led to a significant stock price collapse.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
9h ago
